
OpenAI Cuts GPT-6 API Prices 50% With Sol and Luna Launch
Why did OpenAI cut API prices 50%?
OpenAI (private) cut its GPT-6 API prices 50% to $2.00/M tokens on Tuesday after rival Anthropic launched Claude Opus 5.5 at 40% less, igniting a live frontier-AI price war.
Key numbers
| GPT-6 Sol input price | $2.00/M tokens-50% from GPT-5.6 Sol at $4.00/M |
|---|---|
| GPT-6 Luna input price | $0.10/M tokens-50% from GPT-5.6 Luna at $0.20/M |
| Claude Opus 5.5 input price | $4.00/M tokens-20% list; ~-40% effective workload cost vs. Opus 5 ($5.00/M) |
| GPT-6 cached input discount | 90% off standard rateGitHub: fresh token processing halved across billions of requests (per [1] only) |
| Anthropic annualized revenue | $65BJuly 2026 run rate; $120B+ projected by year-end (per [5] only) |
| Frontier AI API cost decline | ~90–97%for equivalent intelligence since early 2024 |
What happened
OpenAI (private) cut its GPT-6 API prices 50% to $2.00/M tokens on Tuesday after rival Anthropic launched Claude Opus 5.5 at 40% less, igniting a live frontier-AI price war. OpenAI's two new models — Sol, a mid-tier workhorse, and Luna, a lightweight option at just $0.10 per million input tokens — arrived roughly 90 minutes after Anthropic's Opus 5.5. Anthropic cut its flagship list price 20% (from $5.00 to $4.00 per million input tokens), and customers running typical agent workloads should see about 40% lower total bills once faster output and caching improvements are included. Neither company is publicly traded; both are racing to lock in enterprise customers ahead of upcoming IPOs.
Why it matters
API prices are how businesses pay to use artificial intelligence by the token — today's cuts mean companies can now run OpenAI's flagship AI at half last month's cost. For enterprises, this speeds up automation investment; for the broader economy, prices that have already fallen roughly 90% since early 2024 are falling further, squeezing the revenue outlooks both companies need to justify IPO valuations of $1 trillion or more. The price war shows that even dominant AI labs are willing to sacrifice margins to win enterprise market share before going public.
Who this affects
- MarketmixedMedium impact
- Public AI backers Microsoft and Google face margin pressure.
- CompanymixedHigh impact
- OpenAI wins price edge; own margins compress ahead of IPO.
- CompetitorsbearishMedium impact
- Anthropic, Google, and DeepSeek face pressure to match deeper cuts.
- IndustrybullishHigh impact
- Cheaper frontier AI accelerates enterprise adoption across every sector.
OpenAI vs Anthropic, Google, DeepSeek
| OpenAI (GPT-6 Sol)private | ~$1.2T | $2.00 | $10.00 | -50% |
|---|---|---|---|---|
| Anthropic (Claude Opus 5.5)private | ~$965B | $4.00 | $20.00 | -40% eff. |
| Google (Gemini 3.1 Pro)GOOGL | ~$2.3T | $2.00 | $12.00 | — |
| DeepSeek (V4.1 Flash)private | private | $0.15 | ~$0.60 | — |
As of 2026-09-23
How we got here
Frontier AI API costs begin 90%+ multi-year decline for equivalent capability
GPT-5.6 launch: OpenAI overtakes Anthropic on OpenRouter for first time in 2.5 years
Anthropic pushes IPO timeline from October to November 2026
Anthropic launches Claude Opus 5.5 at $4.00/M input, ~40% cheaper on typical workloads
OpenAI releases GPT-6 Sol ($2.00/M) and Luna ($0.10/M), each 50% below prior GPT-5.6 pricing
What to watch
- Anthropic IPO roadshow: will valuation hold above $1.5T amid margin compression?November 2026
- Google and DeepSeek pricing response to the dueling 40–50% cutsQ4 2026
- Enterprise API adoption data: does volume growth offset margin compression for both labs?Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →

Priority Technology Stock Jumps 33% on CEO-Led Buyout
Priority Technology Holdings (PRTH) agrees to go private at $8.05 per share, a 38% premium, in a CEO-led deal.

SanDisk Stock Jumps 6% as Rosenblatt Starts Coverage at Buy
SanDisk (SNDK) gets a $2,400 Rosenblatt target as AI demand locks in 65% of its FY2028 output.

Viking Therapeutics Stock Surges 36% on VK2735 Maintenance Data
Viking Therapeutics (VKTX) shares surged as VK2735 kept 97% of weight loss via less-frequent injection dosing.